drugset
drugset / Trial / NCT07368127

A Study of TPD3310 in Patients With Advanced Malignant Tumors

NCT07368127 ↗

Phase 1 Recruiting 112 enrolled TAIBIDI PHARMACEUTICAL TECHNOLOGY(SHIJIAZHUANG) CO.,LTD.
NaSingle-groupOpen-labelTreatment

Summary

This study is a multicenter, open phase I clinical study of dose escalation,cohort expansion study to evaluate the safety,tolerability,pharmacokinetics,pharmacodynamics, and preliminary efficacy of TPD3310 in patients withadvanced malignant solid tumors.

Timeline

Start
2026-03-05
Primary completion
2028-03-01
Completion
2029-03-01

Drugs

EvaluationDrugModalityDoseRoute
Subject TPD3310 Unknown 50 mg Other
Subject TPD3310 Unknown 100 mg Other
Subject TPD3310 Unknown 200 mg Other
Subject TPD3310 Unknown 350 mg Other
Subject TPD3310 Unknown 500 mg Other
Subject TPD3310 Unknown 650 mg Other

Indications

cancer